Crestchem Limited reported a net profit of ₹271.35 lakh for the financial year ended March 31, 2026, compared to ₹272.65 lakh in the previous year. Revenue from operations for the year increased to ₹2,960.74 lakh from ₹2,507.72 lakh in FY25. For the quarter ended March 31, 2026, the company posted a net profit of ₹110.38 lakh on revenue of ₹1,022.53 lakh.

The Board of Directors approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The board recommended a final dividend of ₹1.50 per equity share of ₹10 each (15%) for FY26, subject to shareholder approval at the 34th Annual General Meeting. Additionally, the board approved the reappointment of Mr. Dipak Narendraprasad Patel, Mrs. Parul Dipak Patel, and Mrs. Tansi Nirmal Patel for five years.

The company informed the exchange that it incorporated a subsidiary, Oleo Biosciences Private Limited, on March 31, 2026, in Bangalore. The subsidiary has not commenced commercial operations, and no significant financial transactions were carried out during the year. The board also approved an investment of up to ₹2.25 crore in the subsidiary via loans, inter-corporate deposits, or equity share capital.

Samir M. Shah & Associates, Chartered Accountants, audited the standalone and consolidated financial results. The trading window for directors and designated personnel, closed since April 1, 2026, will reopen 48 hours after the results are made public.

Standalone Financial Results (Year Ended March 31, 2026)

Crestchem Limited has notified BSE Limited of an upcoming Board of Directors meeting scheduled for Tuesday, May 26, 2026, at 12:15 Noon, pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The meeting will address several significant corporate matters, including the approval of audited financial results for the quarter and financial year ended March 31, 2026, and a recommendation on final dividend.

Key Agenda Items

The board meeting has been convened to deliberate on a broad range of items. The following table summarises the primary agenda points:

Subsidiary Incorporation and Investment

The board will take note of the formation of Oleo Biosciences Private Limited, incorporated on March 31, 2026, and based in Bangalore, Karnataka, bearing CIN No. U20110KA2026PTC218609. The company has not commenced any activity during the financial year ended 2026. Additionally, the board will consider an investment of up to ₹2.25 Crores in the subsidiary under Sections 179 and 186 of the Companies Act, 2013, through permissible means including loans, intercorporate loans, or equity share capital.

Managerial Appointments and Reappointments

The board will consider the reappointment of Mr. Dipak Narendraprasad Patel for a period of five years from October 1, 2026 to September 30, 2031. Similarly, the reappointment of Mrs. Parul Dipak Patel for five years from October 1, 2026 to September 30, 2031, will be considered under Section 188 of the Companies Act, 2013. The appointment of Mrs. Tansi Nirmite Patel for a five-year term from April 1, 2026 to March 31, 2031, under Section 188 of the Companies Act, 2013, is also on the agenda.

Trading Window Closure

In accordance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code for prohibition of insider trading, the trading window for dealing in the securities of the company for directors, officers, key managerial personnel, and designated persons has been closed from April 1, 2026 and will remain closed until 48 hours after the financial results are made public following the said meeting.

The intimation was submitted by Nitin S. Shah, Company Secretary and Compliance Officer (ACS-7088), on behalf of Crestchem Limited, dated May 18, 2026.